The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.

ABSTRACT:

Background

Parkinson's disease is a progressive neurodegenerative disease, which significantly impacts patients' quality of life and is associated with high treatment and direct healthcare costs. In England, levodopa/carbidopa intestinal gel (LCIG) is indicated for the treatment of levodopa-responsive advanced Parkinson's disease with troublesome motor fluctuations when available combinations of medicinal products are unsatisfactory.

Objective

We aimed to determine the cost effectiveness of LCIG compared to the standard of care for patients with advanced Parkinson's disease in England, using real-world data.

Methods

A Markov model was adapted from previous published studies, using the perspective of the English National Health System and Personal and Social Services t

SUBMITTER: Chaudhuri KR 

PROVIDER: S-EPMC9095547 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature